




Research Transparency Panel Meeting Summary

Novartis

3rd December 2024

15:00–16:30



Data Access Proposal Request

Flatiron Health UK RWD Products

- Prostate Cancer

Attendees

FLATIRON HEALTH UK

- Adam Manhi (chair)
- Emma Salib (programme manager)

RESEARCH TRANSPARENCY PANEL

- Jennifer McCaffery (lay)
- Hayley Hall (lay)
- Sonia Patton (patient)
- Trishna Bharadia (patient)
- Yanrong Jiang (clinical)

Conflicts of interest

No conflicts declared by panel

Decision outcome

Approved

Summary of discussion

- Broad agreement the lay summary was clear, well-written and easy to follow.
- Clear cohort with unmet need and limited treatment options which become less effective over time.
- Comprehensive explanation of use cases, including analyses and patient benefit.
- Clear case for why access to RWD is required, giving more representative insights than clinical trials.
- Transparent explanation of previous work with Flatiron and positive impact.
- The panel raised several comments on other aspects of the application including:
 - Patient cohort with 'unmet need' could have been elaborated on further (e.g. # patients; survival rates; side effects of current medications).
 - Further detail on why Novartis is seeking to gain regulatory approval for the drug without the need for one prior line of chemotherapy.
 - More detail could have been provided on DEI (e.g. existing health inequalities; examples of Novartis' DEI work).

- Would have liked more information on how Novartis would engage with patients through the process, including integrating feedback and disseminating findings.